Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Chiho Ono"'
Autor:
Naoto Takahashi, Jorge E. Cortes, Emiko Sakaida, Kenichi Ishizawa, Takaaki Ono, Noriko Doki, Itaru Matsumura, Valentín García-Gutiérrez, Gianantonio Rosti, Chiho Ono, Masayuki Ohkura, Yusuke Tanetsugu, Andrea Viqueira, Tim H. Brümmendorf
Publikováno v:
International Journal of Hematology. 115:838-851
Bosutinib has been investigated in multiple clinical trials globally, including Japan, for treatment of chronic myeloid leukemia (CML). A pooled analysis of seven Pfizer-sponsored clinical trials evaluated the safety of bosutinib in Japanese (n = 138
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03ba140070da2f204e96c7392d581888
https://doi.org/10.1007/s12185-022-03314-y
https://doi.org/10.1007/s12185-022-03314-y
Autor:
Takaaki Ono, Masayuki Hino, Itaru Matsumura, Shin Fujisawa, Kenichi Ishizawa, Emiko Sakaida, Naohiro Sekiguchi, Chiho Ono, Mana Aizawa, Yusuke Tanetsugu, Yuichiro Koide, Naoto Takahashi
Publikováno v:
International journal of hematology. 116(6)
Bosutinib has been evaluated for treatment of chronic-phase chronic myeloid leukemia (CP-CML) in several clinical studies, including in Japan. This open-label, single-arm, phase 2 study evaluated the efficacy and safety of bosutinib at a starting dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a86380b6eb849e4cbb970ec3685bf076
https://pubmed.ncbi.nlm.nih.gov/35963986
https://pubmed.ncbi.nlm.nih.gov/35963986
Autor:
Yosuke Fujii, Chul Won Jung, Ming Chung Wang, Barbara Sleight, Miyako Matsumizu, Erik Vandendries, Naohito Fujishima, Kiyoshi Ando, Toshiki Uchida, Chiho Ono, M. Luisa Paccagnella, Masayuki Hino, Yeow Tee Goh, Yasushi Onishi
Publikováno v:
International Journal of Hematology. 110:709-722
Inotuzumab ozogamicin (InO) is a targeted treatment for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). InO was previously studied in INO-VATE, an international, open-label, randomized phase 3 trial comparing InO against
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f5446811d2436a5fc56cf239a24d381
https://doi.org/10.1007/s12185-019-02749-0
https://doi.org/10.1007/s12185-019-02749-0
Autor:
Tontanai Numbenjapon, Young Rok Do, Jorge E. Cortes, Liang Piu Koh, Dae Young Zang, Charles Chuah, Tim H. Brümmendorf, Kiat Hoe Ong, Masayuki Ohkura, Andrea Viqueira, Chiho Ono
Publikováno v:
International journal of hematology. 114(1)
Bosutinib is approved in the United States, Europe, Japan, and other countries for treatment of newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML), and CML resistant/intolerant to prior therapy. In the phase 3 BFORE trial (Clinicaltria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70264ffc0ec2eb03ad3961a2c6253bdc
https://pubmed.ncbi.nlm.nih.gov/33851349
https://pubmed.ncbi.nlm.nih.gov/33851349
Autor:
Takaaki Ono, Yusuke Tanetsugu, Shin Fujisawa, Itaru Matsumura, Yuichiro Koide, Emiko Sakaida, Naohiro Sekiguchi, Mana Aizawa, Naoto Takahashi, Chiho Ono, Masayuki Hino, Kenichi Ishizawa
Publikováno v:
Blood. 138:2557-2557
Introduction : Bosutinib is approved in Japan for patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic phase (CP) chronic myeloid leukemia (CML) and Ph+ CML resistant/intolerant to prior therapy. In the primary report of a pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d0c7ca3c096ca6d96e63a9b007998a0
https://doi.org/10.1182/blood-2021-145164
https://doi.org/10.1182/blood-2021-145164
Autor:
Geoffrey Chan, Mohammed Naveed Shaik, Tomoki Naoe, Yosuke Fujii, Wataru Munakata, Toshihiro Miyamoto, Adrian Woolfson, Goichi Yoshimoto, Yosuke Minami, Yukio Kobayashi, Xianxian Zheng, Chiho Ono, Mari Ikuta, Hironobu Minami, Masahiro Kobayashi, Yasushi Onishi
Publikováno v:
Cancer Science
Summary The hedgehog signaling pathway regulates multiple morphogenetic processes during embryogenesis. Aberrant activation of the hedgehog pathway signal transduction in adult tissues is associated with the pathogenesis of hematologic malignancies a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::351c6c85fb18f070e3d32565540716ad
http://europepmc.org/articles/PMC5543507
http://europepmc.org/articles/PMC5543507
Autor:
Chiaki Nakaseko, Chiho Ono, Naoto Takahashi, Kazunori Ohnishi, Yukio Kobayashi, Koichi Miyamura, Yosuke Fujii, Yuichiro Koide
Publikováno v:
International Journal of Hematology. 106:398-410
This long-term follow-up of a completed phase 1/2 study assessed the safety and efficacy of bosutinib in Japanese Philadelphia chromosome-positive, chronic phase (CP) or advanced phase (ADV) chronic myeloid leukemia patients who were resistant/refrac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66d6a5bb83d658dbe96152a03aa8753c
https://doi.org/10.1007/s12185-017-2239-8
https://doi.org/10.1007/s12185-017-2239-8
Publikováno v:
Drug Metabolism and Disposition. 45:390-398
Bosutinib is an orally available Src/Abl tyrosine kinase inhibitor indicated for the treatment of patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Bosutinib is predominantly metabolized by CYP3A4 as the primary clearance m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce4d6c9be3837937ac6e347b3626298f
https://doi.org/10.1124/dmd.116.074450
https://doi.org/10.1124/dmd.116.074450
Autor:
Ichiro Ieiri, Masato Fukae, Chiho Ono, Misaki Suzuki, Akiyuki Suzuki, Yuichi Yamamoto, Katsuomi Ichikawa, Hironori Kikkawa
Publikováno v:
Pharmacogenomics. 14:1745-1764
Drug transporters, together with drug metabolic enzymes, are major determinants of drug disposition and are known to alter the response to many commonly used drugs. Substantial frequency differences for known variants exist across geographic regions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d126d72a802a07e538b2d0a005e7d93d
https://doi.org/10.2217/pgs.13.171
https://doi.org/10.2217/pgs.13.171
Autor:
Larry M. Tremaine, Emi Kimoto, Chiho Ono, Katsuomi Ichikawa, Ayman El-Kattan, Misaki Suzuki, Hironori Kikkawa, Bo Feng, Yuichi Yamamoto, Akiyuki Suzuki, Joel Clay Stephens, Manthena V.S. Varma, Yurong Lai
Publikováno v:
Expert Opinion on Drug Metabolism & Toxicology. 8:723-743
Drug transporter proteins are expressed on the cell membrane, regulating substrate exposure in systemic circulation and/or peripheral tissues. Genetic polymorphism of drug transporter genes encoding these proteins could alter the functional activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::235aee34ba03653d5771a222adbda08d
https://doi.org/10.1517/17425255.2012.678048
https://doi.org/10.1517/17425255.2012.678048